Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab

Alattar, 2020, Tocilizumab for the treatment of severe COVID‐19, J. Med. Virol. Baker, 2020, The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic, Mult. Scler. Relat. Disord., 10.1016/j.msard.2020.102174 Bohwmick, 2016, Humanized monoclonal antibody Alemtuzumab treatment in transplant, Exp. Clin. Transplant, 14, 17 Brownlee, 2020, Treating multiple sclerosis and neuromyelitis optica spectrum disease during the COVID-19 pandemic, Neurology., 10.1212/WNL.0000000000009507 Cohen, 2012, Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial, Lancet, 24, 1819, 10.1016/S0140-6736(12)61769-3 Coles, 2012, Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial, Lancet, 24, 1829, 10.1016/S0140-6736(12)61768-1 Coles, M., from the MS Advisory Group. ABN guidance on the use of disease-modifying therapies in multiple sclerosis in response to the threat of a coronavirus epidemic 2020, https://cdn.ymaws.com/www.theabn.org/resource/collection/65C334C7-30FA-45DB-93AA-74B3A3A20293/02.04.20_ABN_Guidance_on_DMTs_for_MS_and_COVID19_VERSION_4_April_2nd.pdf. Access May 11th, 2020. Dong, 2020, Epidemiology of COVID-19 among children in China, Pediatrics, 10.1542/peds.2020-0702 Giovannoni, 2020, The COVID-19 pandemic and the use of MS disease-modifying therapies, Mult. Scler. Relat. Disord., 39, 10.1016/j.msard.2020.102073 Giovannoni, 2020, Anti-CD20 Immunosuppressive disease-modifying therapies and COVID-19, Mult. Scler. Relat. Disord., 41, 10.1016/j.msard.2020.102135 Guan, 2020, Clinical characteristics of coronavirus disease 2019 in China, N. Engl. J. Med., 382, 1708, 10.1056/NEJMoa2002032 Hartung, 2015, Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis, Mult. Scler., 21, 22, 10.1177/1352458514549398 Li, 2018, Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis, Clin. Exp. Immunol., 194, 295, 10.1111/cei.13208 Liu, 2020, Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients, EBioMedicine, 55, 10.1016/j.ebiom.2020.102763 Matías-Guiu, 2020, Management of neurological care during the COVID-19 pandemic, Neurologia. Montero-Escribano, 2020, Anti-CD20 and Covid-19 in Multiple Sclerosis and related disorders: a case series of 60 patients from Madrid, Spain, Mult. Scler. Relat. Disord., 10.1016/j.msard.2020.102185 Myers, 2020, Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California, JAMA, 10.1001/jama.2020.7202 Novi, 2020, COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?, Mult. Scler. Relat. Disord., 42, 10.1016/j.msard.2020.102120 Quinti, 2020, A possible role for B cells in COVID-19?: lesson from patients with Agammaglobulinemia, J. Allergy Clin. Immunol., 10.1016/j.jaci.2020.04.013 Than Le, 2020, The COVID-19 vaccine development landscape, Nat. Rev. Drug Discov., 19, 305, 10.1038/d41573-020-00073-5 Thompson, 2018, Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria, Lancet Neurol., 17, 162, 10.1016/S1474-4422(17)30470-2 Sormani, 2020, An Italian programme for COVID-19 infection in multiple sclerosis, Lancet Neurol., 10.1016/S1474-4422(20)30147-2 Wang, 2020, The risk of children hospitalized with severe COVID-19 in Wuhan, Pediatr. Infect. Dis. J., 10.1097/INF.0000000000002739 Zhang, 2013, Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis, J. Immunol., 91, 5867, 10.4049/jimmunol.1301926 McCarthy, 2013, Immune competence after alemtuzumab treatment of Multiple Sclerosis, Neurology, 81, 872, 10.1212/WNL.0b013e3182a35215